Abstract
Overview
Introduction
Datamonitor expects the cardiovascular market to remain stable with sales only
showing negligible growth between 2006 and 2016, below the 3% growth predicted
for the SU sold. Generic products will become increasingly important as the
majority of products will have lost IP protection, accounting for 30% of
cardiovascular sales and 65% of SU sold in 2016.
Scope
- Comprehensive analysis of the cardiovascular market by disease area in
each of the seven major markets
- An assessment of trends within the cardiovascular market between 2003 and
2006.
- Intellectual Property risk assessment for Top 10 brands in each market.
- Forecast models for key brands, active agents and pipeline products up to
2016.
Report Highlights
The cardiovascular market in the seven major markets is a mature market with
negligible sales growth between 2006 and 2016. Growth of SU sold in the
cardiovascular market is expected to increase by 3%, driven by population
growth, leaving an effective cardiovascular sales growth of -3%.
Use of generics will increase as key products lose patent protection and
healthcare providers push for greater cost containment. Patent expiries during
the pivotal 2010-13 window expose $30.9 billion worth of branded drugs to
generic competition.
Cardiovascular pipeline products are unlikely to make a significant impact on
the market with only 16% ($11.9 billion) of 2016 sales generated from the
current pipeline. A number of blockbuster products are likely to be launched
but the sales are likely to be greatly reduced from the levels seen in 2006.
Reasons to Purchase
- Understand market specific drivers and predict the future potential of key
cardiovascular brands
- Quantify the impact of key patent expiries and product launches and gain a
valuable insight into the market dynamics
- Consider, assess and react to opportunities and risks influencing the
leading cardiovascular brands
View Cart
